Loading...

MGNX MACROGENICS INC Contract Awards 8-K Filing

MCRG

MGNX

MACROGENICS INC

(MGNX)

2024 8-K

Royalty Agreement Update

FDA Approval Update

Financial Results Report

Director Departure

FDA Clinical Hold

Management Change

Financial Results Report

Financial Results Announced

Executive Appointment

Asset Acquisitions

Financial Statements

Financial Results

Management Changes

Financial Results

Clinical Trial Update

Earnings Report

Amendment to Collaboration ...

Annual Meeting of Stockholders

Financial Results Announcement

Results of Operations and F...

Results of Operations and F...

Termination of Material Def...

Results of Operations and F...

Annual Meeting of Stockholders

Results of Operations and F...

Results of Operations and F...

Regulation FD Disclosure

Purchase Agreement with DRI...

Appointment of Director

External Links:

MacroGenics, Inc. announced updated efficacy and safety data from its Phase 2 TAMARACK trial for vobramitamab duocarmazine in prostate cancer, presented at the ESMO Congress and discussed in an investor call.

AI Assistant

MACROGENICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.